MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson’s disease progression
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson’s disease progression ; volume:50 ; number:11 ; day:9 ; month:9 ; year:2023 ; pages:8889-8899 ; date:11.2023
Molecular biology reports ; 50, Heft 11 (9.9.2023), 8889-8899, 11.2023
- Urheber
-
Geng, Xin
Li, Shipeng
Li, Jinghui
Qi, Renli
Zhong, Lianmei
Yu, Hualin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11033-023-08775-w
- URN
-
urn:nbn:de:101:1-2024012911162632331319
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Geng, Xin
- Li, Shipeng
- Li, Jinghui
- Qi, Renli
- Zhong, Lianmei
- Yu, Hualin
- SpringerLink (Online service)
Ähnliche Objekte (12)
MDMA ("Ecstasy") in Tiermodellen des Morbus Parkinson
Prevention of progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Genetically-informed prediction of short-term Parkinson’s disease progression
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Correction: The deficiency of Maged1 attenuates Parkinson’s disease progression in mice
MDMA ("Ecstasy") in Tiermodellen des Morbus Parkinson
Prevention of progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Genetically-informed prediction of short-term Parkinson’s disease progression
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Correction: The deficiency of Maged1 attenuates Parkinson’s disease progression in mice
MDMA ("Ecstasy") in Tiermodellen des Morbus Parkinson
Prevention of progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Genetically-informed prediction of short-term Parkinson’s disease progression
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease